Search

Failed Clinical Trial Puts Eli Lilly Cancer Drug in Limbo

FAILED CLINICAL TRIAL PUTS ELI LILLY CANCER DRUG IN LIMBO

An Eli Lilly drug on the market for a rare form of cancer is now in limbo, after it failed a trial needed to retain the FDA approval...

 
 
 
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More

NOTES FROM THE JPM19 VORTEX: PRICE APOCALYPSE, CELGENE FALLOUT & MORE

[ Editor's note: Ben Fidler and Sarah de Crescenzo coauthored this report .] It is here, and then it is gone. But by the time everyone...

 
 
 
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More

BIO ROUNDUP: $74B FOR CELGENE, TWO CAR-T TALES, READY FOR SF & MORE

In 2018, my Exome colleagues and I published hundreds of stories about health, medicine, the biopharma industry, government policy,...

 
 
 

THE IMPACT OF THE FECAL MICROBIOME ON CANCER IMMUNOTHERAPY

Abstract Recent advances in culture-free methods of studying the human microbiome, coupled with strong bioinformatics tools, have provided...

San Francisco Biotech: The Next Generation-Photos and Takeaways

SAN FRANCISCO BIOTECH: THE NEXT GENERATION-PHOTOS AND TAKEAWAYS

View the Slideshow Among the life science companies developing new approaches to disease today are those that will shape the healthcare...

 
 
 
Gilead Sciences Commits $150M to Agenus in Cancer Drug R&D Pact

GILEAD SCIENCES COMMITS $150M TO AGENUS IN CANCER DRUG R&D PACT

For the second time this week, Gilead Sciences has partnered with a Boston-area biotech, this time with a deal that covers up to five...

Kineta Gets $15M in New Cancer Drug Partnership with Pfizer

KINETA GETS $15M IN NEW CANCER DRUG PARTNERSHIP WITH PFIZER

Seattle biotech company Kineta continues to expand its roster of drug development partners, announcing on Monday it has entered into...

 
 
 
15 For '19: Key Clinical Data To Watch For Next Year

15 FOR '19: KEY CLINICAL DATA TO WATCH FOR NEXT YEAR

It can take decades and billions of dollars to develop a drug, and its fate-and often that of its developer-rests in the outcome of...

Bio Roundup: Eli Lilly Tries Tau, Generic Insulin, NASH Cash & More

BIO ROUNDUP: ELI LILLY TRIES TAU, GENERIC INSULIN, NASH CASH & MORE

Pharmaceutical industry critics lament the cost of rare disease drugs, but some of the steepest price hikes have come on widely used...

 
 
 
OncoMed's Saga Ends in Reverse Merger with UK-Based Mereo BioPharma

ONCOMED'S SAGA ENDS IN REVERSE MERGER WITH UK-BASED MEREO BIOPHARMA

OncoMed Pharmaceuticals attracted hundreds of millions of dollars from investors and pharmaceutical partners with compounds it developed...

AMGEN ANNOUNCES FIRST-IN-HUMAN DATA EVALUATING INVESTIGATIONAL NOVEL BITE® IMMUNOTHERAPIES AMG 420 AND AMG 330 AT ASH 2018

Phase 1 Results of Amgen's BiTE® Platform in Heavily Pre-Treated Patients With Multiple Myeloma and Acute Myeloid LeukemiaFDA Grants...

 
 
 
Bio Roundup: Moderna's IPO, Arena's Comeback, E-Cig Survey & More

BIO ROUNDUP: MODERNA'S IPO, ARENA'S COMEBACK, E-CIG SURVEY & MORE

Thanksgiving is around the corner and this week delivered a bounty of deals that have a number of life science companies expressing...

Celgene Doubles Down on Dragonfly, Pays $50M to Expand Cancer Pact

CELGENE DOUBLES DOWN ON DRAGONFLY, PAYS $50M TO EXPAND CANCER PACT

Celgene's collaboration with Dragonfly Therapeutics is less than 18 months old, but the pharmaceutical company is already expanding...

 
 
 
BIO Celebrates 300 Biotech IPOs since Enactment of the JOBS Act

BIO CELEBRATES 300 BIOTECH IPOS SINCE ENACTMENT OF THE JOBS ACT

The biotech industry recently realized its 300 th IPO since the Jumpstart Our Business Startups Act was enacted in 2012. This marks...

Immune Cells Present Inside the Tumor can be Identified Using This Approach

IMMUNE CELLS PRESENT INSIDE THE TUMOR CAN BE IDENTIFIED USING THIS APPROACH

By identifying immune cells inside the tumor, doctors will be able to analyze which immunotherapy is working and which one is not,...

 
 
 
Bio Roundup: Alzheimer's Puzzle, ESMO Assessed, Drug Prices & More

BIO ROUNDUP: ALZHEIMER'S PUZZLE, ESMO ASSESSED, DRUG PRICES & MORE

In the biotech investment and research communities this week, much of the attention was turned to Europe. Munich, Germany, hosted the...

Immunotherapy Drugs to be Delivered to Tumor's Doorstep: Study

IMMUNOTHERAPY DRUGS TO BE DELIVERED TO TUMOR'S DOORSTEP: STUDY

New nanodevice may deliver immunotherapy drugs directly to the tumor, thereby preventing the unwanted side effects that come with standard...